Fusion Pharmaceuticals Inc. focuses on developing radiopharmaceuticals as precision medicines. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.
Market Cap | 336.836 Million | Shares Outstanding | 63.196 Million | Avg 30-day Volume | 52.825 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.99 |
Price to Revenue | 224.2649 | Debt to Equity | 0.1711 | EBITDA | -95.555 Million |
Price to Book Value | 1.0095 | Operating Margin | -10217.2566 | Enterprise Value | 15.494 Million |
Current Ratio | 12.734 | EPS Growth | -0.026 | Quick Ratio | 12.117 |
1 Yr BETA | 0.445 | 52-week High/Low | 5.63 / 1.98 | Profit Margin | -10176.3274 |
Operating Cash Flow Growth | -19.4324 | Altman Z-Score | -0.0116 | Free Cash Flow to Firm | -69.963 Million |
Earnings Report | 2023-08-08 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
LEAMON CHRISTOPHER P CHIEF SCIENTIFIC OFFICER |
|
250,000 | 2023-01-05 | 1 |
CROWLEY JOHN J CHIEF FINANCIAL OFFICER |
|
250,000 | 2023-01-05 | 1 |
VALLIANT JOHN CHIEF EXECUTIVE OFFICER |
|
500,000 | 2023-01-05 | 1 |
BURAK ERIC CHIEF TECHNOLOGY OFFICER |
|
250,000 | 2023-01-05 | 1 |
RAWAT MOHIT PRESIDENT AND CBO |
|
300,000 | 2023-01-05 | 1 |
|
42,093 | 2022-11-11 | 2 | |
BOBILEV DMITRI CHIEF MEDICAL OFFICER |
|
0 | 2022-11-07 | 2 |
|
56,400 | 2022-08-11 | 2 | |
|
17,000 | 2022-06-14 | 1 | |
|
17,000 | 2022-06-14 | 1 | |
|
17,000 | 2022-06-14 | 1 | |
|
17,000 | 2022-06-14 | 1 | |
O'LEARY JAMES J CHIEF MEDICAL OFFICER |
|
161,022 | 2022-02-01 | 0 |
|
17,000 | 2021-06-14 | 0 | |
|
No longer subject to file | 2020-12-24 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
|
3,122,770 | 2020-06-30 | 0 | |
|
3,807,247 | 2020-06-30 | 0 | |
|
No longer subject to file | 2020-06-30 | 0 | |
|
0 | 2020-06-25 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 22:15:04 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 21:45:05 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 21:15:04 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 20:45:04 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 20:15:06 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 19:45:04 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 19:15:04 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 18:45:04 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 18:15:03 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 17:45:05 UTC | -14.1046 | 19.1746 | 400000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 17:15:04 UTC | -14.1046 | 19.1746 | 550000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 16:45:03 UTC | -14.1046 | 19.1746 | 550000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 16:15:04 UTC | -14.1046 | 19.1746 | 100000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 15:45:04 UTC | -14.1046 | 19.1746 | 100000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 15:15:04 UTC | -14.1046 | 19.1746 | 100000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 14:45:04 UTC | -14.1046 | 19.1746 | 100000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 14:15:03 UTC | -14.1046 | 19.1746 | 100000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 13:45:03 UTC | -12.846 | 17.916 | 100000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 13:15:04 UTC | -12.846 | 17.916 | 250000 |
FUSION PHARMACEUTICALS INC FUSN | 2023-06-07 12:45:04 UTC | -12.846 | 17.916 | 250000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|